|
MLL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.43830000026912E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.86730000001556E-06 |
| Normal-vs-Stage2 |
1.560580E-03 |
| Normal-vs-Stage3 |
1.33150002135096E-09 |
| Normal-vs-Stage4 |
7.3641999998042E-07 |
| Stage1-vs-Stage2 |
6.332800E-01 |
| Stage1-vs-Stage3 |
3.167700E-02 |
| Stage1-vs-Stage4 |
1.759010E-01 |
| Stage2-vs-Stage3 |
4.976400E-02 |
| Stage2-vs-Stage4 |
1.596210E-01 |
| Stage3-vs-Stage4 |
7.045400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.48569999975012E-07 |
| Normal-vs-AfricanAmerican |
3.864300E-03 |
| Normal-vs-Asian |
1.815380E-04 |
| Caucasian-vs-AfricanAmerican |
6.681000E-01 |
| Caucasian-vs-Asian |
7.604000E-01 |
| AfricanAmerican-vs-Asian |
8.387800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.91199999563818E-08 |
| Normal-vs-Female |
2.85850000003585E-07 |
| Male-vs-Female |
5.001600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.55140000002163E-06 |
| Normal-vs-Age(41-60Yrs) |
1.51171999999145E-05 |
| Normal-vs-Age(61-80Yrs) |
6.7944000425868E-09 |
| Normal-vs-Age(81-100Yrs) |
2.675600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.041400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.101030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.614000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.644000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.351800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.410400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.381630E-04 |
| Classical-VS-Follicular |
4.715600E-01 |
| Classical-VS-Other |
1.784830E-01 |
| Classical-VS-Normal |
3.65610000052641E-07 |
| Tall-VS-Follicular |
3.196000E-02 |
| Tall-VS-Other |
8.171200E-01 |
| Tall-VS-Normal |
1.28429999968205E-09 |
| Follicular-VS-Other |
4.987800E-01 |
| Follicular-VS-Normal |
1.031040E-04 |
| Other-VS-Normal |
4.355500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.0515000004041E-07 |
| Normal-vs-N1 |
6.3438999999943E-05 |
| N0-vs-N1 |
9.149800E-01 |
|
|
